Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies

• Published in: BJU international 2005-09, Vol.96 (4), p.572-577
• Main Authors: Roehrborn, Claus G, Lukkarinen, Olavi, Mark, Stephen, Siami, Paul, Ramsdell, Joe, Zinner, Norman
• Format: Article
• Language: English
• Subjects: 5-alpha Reductase Inhibitors; Aged; Azasteroids - therapeutic use; Double-Blind Method; Dutasteride; Follow-Up Studies; Humans; Isoenzymes - antagonists & inhibitors; Male; Middle Aged; Prostatic Hyperplasia - drug therapy; Time Factors; Treatment Outcome
• ISSN: 1464-4096

To report additional analyses of efficacy over the initial 2 years and during a 2-year open-label extension of the three pivotal phase 3 studies in which dutasteride, a dual inhibitor of type 1 and 2 5alpha-reductase, was shown to be effective and well tolerated. All patients in the placebo and active groups were eligible for entry into the 2-year open-label extension, with all receiving dutasteride 0.5 mg daily. Mean changes from baseline were calculated for the American Urologic Association Symptom Index (AUA-SI) score at each scheduled time in the double-blind and open-label phase. The additional analyses included a breakdown of the AUA-SI score, including stratifying patients by symptom severity, assessment by baseline age and prostate volume, and the evaluation of symptoms responders. There was a clinically meaningful improvement in AUA-SI in patients on dutasteride in the double-blind phase, but not in those on placebo. At 48 months, patients on dutasteride in both study phases had greater improvements in AUA-SI score and individual question scores than those on dutasteride in the open-label phase only. The proportion of patients with severe symptoms declined in both study groups, although these changes were more profound in those receiving dutasteride for the 4-year duration of the study. In men with symptomatic benign prostatic hyperplasia, long-term (4-year) treatment with the dual isozyme 5alpha-reductase inhibitor dutasteride resulted in sustained and continued improvements in symptoms and flow rate. For 4 vs 2 years, longer dutasteride therapy resulted in greater symptom improvement.